Sagimet Biosciences Inc. Accounts Payable
Sagimet Biosciences Inc. (SGMT) had Accounts Payable of $1.13 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-11
- 2026-06-30: Accounts Payable, Current $1.13M.
- 2026-03-31: Accounts Payable, Current $2.30M.
- 2025-12-31: Accounts Payable, Current $1.31M.
- 2025-09-30: Accounts Payable, Current $4.24M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $1.13M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $2.30M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $1.31M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $4.24M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $1.92M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $3.22M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.43M 10-K · filed 2026-03-11 |
| 2024-09-30 | $1.15M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $1.99M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $531.00K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $186.00K 10-K · filed 2025-03-12 |
| 2023-09-30 | $1.70M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $2.72M 10-Q · filed 2023-08-21 |
| 2022-12-31 | $1.13M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |